Kymera Therapeutics: Buy Rating Supported by Innovative Drug Discovery and Strategic Partnerships

Kymera Therapeutics maintains a Buy rating due to its innovative drug discovery approach, promising clinical data, and partnerships with major pharma companies like Sanofi and Gilead. Analyst Judah Frommer predicts a price target of $70, citing the potential of KT-621 and other pipeline candidates to achieve significant market success. BTIG also maintains a Buy rating with a $59 price target.